<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04698993</url>
  </required_header>
  <id_info>
    <org_study_id>Dräger Antigen Test SARS-CoV-2</org_study_id>
    <nct_id>NCT04698993</nct_id>
  </id_info>
  <brief_title>Dräger COVID-19 Antigen Test Clinical Performance Study</brief_title>
  <official_title>Dräger Antigen Test SARS-CoV-2 Clinical Performance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drägerwerk AG &amp; Co. KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Drägerwerk AG &amp; Co. KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to demonstrate suitability of the Dräger Antigen Test for SARS-CoV-2&#xD;
      detection in clinical nasal specimens. Real-time polymerase chain reaction (RT-PCR) on&#xD;
      specimens collected by pharyngeal swabs serves as a reference method.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Dräger Antigen Test SARS-CoV-2 is a rapid lateral flow immunoassay for the qualitative&#xD;
      detection of SARS-CoV-2 nucleoprotein directly from less invasive nasal swabs, to be&#xD;
      performed at the point of care. The test kit contains all components required to carry out a&#xD;
      test detecting SARS-CoV-2 nucleoprotein.&#xD;
&#xD;
      The study is designed to demonstrate suitability of the Dräger Antigen Test for SARS-CoV-2&#xD;
      detection in clinical nasal specimens. Real-time polymerase chain reaction (RT-PCR) on&#xD;
      specimens collected by pharyngeal swabs serves as a reference method.&#xD;
&#xD;
      The goal of the study is to compare Dräger test results to the corresponding PCR data for&#xD;
      overall sensitivity and specificity. Specimens are collected from patients showing COVID-19&#xD;
      symptoms as well as asymptomatic participants. Participants are recruited across all genders&#xD;
      and eligible age groups. Study staff records participants' information such as symptoms and&#xD;
      time since symptom onset. For each study participant, the specimen for RT-PCR is collected&#xD;
      first, then the Dräger test specimen. The Dräger test result is read after 15 min to 20 min.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">February 12, 2021</start_date>
  <completion_date type="Actual">March 22, 2021</completion_date>
  <primary_completion_date type="Actual">March 22, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>Through study completion, an average of 1 1/2 month</time_frame>
    <description>Sensitivity (true positive rate) of antigen test in symptomatic participants compared with reference standard PCR test (at a threshold of &gt;=10^6 RNA copies/ml for positive PCR results)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>Through study completion, an average of 1 1/2 month</time_frame>
    <description>Specificity (true negative rate) of antigen test in symptomatic participants compared with reference standard PCR test (at a threshold of &gt;=10^6 RNA copies/ml for positive PCR results)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity in Relation to the Cycle Threshold Value of the Reference RT-PCR (in the Symptomatic Group)</measure>
    <time_frame>Through study completion, an average of 1 1/2 month</time_frame>
    <description>Description of relationship between cycle threshold value of the reference RT-PCR and Dräger test performance.&#xD;
Presented is the sensitivity(true positive rate) in the symptomatic group at a cycle threshold of &lt;22</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity in Relation to the Time Since Symptom Onset (in the Symptomatic Group)</measure>
    <time_frame>Through study completion, an average of 1 1/2 month</time_frame>
    <description>Description of relationship between days since symptom onset and Dräger test performance.&#xD;
Presented is the sensitivity(true positive rate) in the symptomatic group at days since symptom onset &lt;5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity in Asymptomatic Participants</measure>
    <time_frame>Through study completion, an average of 1 1/2 month</time_frame>
    <description>Specificity of the antigen test in at least 100 asymptomatic participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Nosebleed or Unbearable Pain During or Immediately After Specimen Collection</measure>
    <time_frame>Through study completion, an average of 1 1/2 month</time_frame>
    <description>Record of occurrence of lasting nosebleed or unbearable pain during or immediately after specimen collection</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">388</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Symptomatic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Collection of specimens from symptomatic COVID-19 positive participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dräger Antigen Test SARS-CoV-2</intervention_name>
    <description>Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
    <arm_group_label>Asymptomatic</arm_group_label>
    <arm_group_label>Symptomatic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must require SARS-CoV-2 testing for the following reasons:&#xD;
&#xD;
               -  COVID-19 symptoms (Fever, cough and/or sore throat, fatigue/ general feeling of&#xD;
                  weakness, loss of sense of smell and/or taste, shortness of breath, muscle&#xD;
                  stiffness/ body aches, head cold/ running nose, etc.) on the day of testing, or&#xD;
&#xD;
               -  Known or suspected exposure to SARS-CoV-2 (contact persons etc.), or&#xD;
&#xD;
               -  Member of a group of high risk of exposure such as healthcare workers etc., or&#xD;
&#xD;
               -  Require screening for any other reason, e.g. doctor's orders, hygiene directive&#xD;
                  etc.&#xD;
&#xD;
          -  Participant must be of legal age and must be able to understand the procedure and&#xD;
             letter of consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients younger than 18 years old are excluded from the study.&#xD;
&#xD;
          -  Pregnant or breastfeeding patients are excluded from the study.&#xD;
&#xD;
          -  Patients unable to provide written informed consent are excluded.&#xD;
&#xD;
          -  Patients with bleeding disorder are excluded from the study as a precaution.&#xD;
&#xD;
          -  Hospitalized patients/inpatients are excluded.&#xD;
&#xD;
          -  Application of nasal spray within 15 min prior to testing.&#xD;
&#xD;
          -  Participants with symptoms on the day of testing are excluded, if any of their&#xD;
             symptoms started more than 14 days prior to testing.&#xD;
&#xD;
          -  Asymptomatic participants are excluded, if they experienced any symptoms in the 14&#xD;
             days prior to testing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Zickler, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.mdpi.com/2077-0383/10/10/2099</url>
    <description>Results publication - Accuracy of a Novel SARS-CoV-2 Antigen-Detecting Rapid Diagnostic Test from Standardized Self-Collected Anterior Nasal Swabs</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <results_first_submitted>June 16, 2021</results_first_submitted>
  <results_first_submitted_qc>June 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 25, 2021</results_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antigen test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 11, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT04698993/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Symptomatic</title>
          <description>Collection of specimens from symptomatic COVID-19 positive participants&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
        </group>
        <group group_id="P2">
          <title>Asymptomatic</title>
          <description>Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="275"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="272"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>PCR results not accessible</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>incomplete documentation of kit assessment prior to testing</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Symptomatic</title>
          <description>Collection of specimens from symptomatic COVID-19 positive participants&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
        </group>
        <group group_id="B2">
          <title>Asymptomatic</title>
          <description>Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="275"/>
            <count group_id="B2" value="113"/>
            <count group_id="B3" value="388"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="275"/>
                    <count group_id="B2" value="113"/>
                    <count group_id="B3" value="388"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.6" lower_limit="18" upper_limit="73"/>
                    <measurement group_id="B2" value="32.5" lower_limit="18" upper_limit="61"/>
                    <measurement group_id="B3" value="34.0" lower_limit="18" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="275"/>
                    <count group_id="B2" value="113"/>
                    <count group_id="B3" value="388"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="211"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="275"/>
                    <count group_id="B2" value="113"/>
                    <count group_id="B3" value="388"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity</title>
        <description>Sensitivity (true positive rate) of antigen test in symptomatic participants compared with reference standard PCR test (at a threshold of &gt;=10^6 RNA copies/ml for positive PCR results)</description>
        <time_frame>Through study completion, an average of 1 1/2 month</time_frame>
        <population>8 symptomatic participants with low RNA copy number were excluded for the calculation of the primary endpoint As this endpoint only considers the sensitivity in symptomatic participants, no numbers are shown for the asymptomatic group</population>
        <group_list>
          <group group_id="O1">
            <title>Symptomatic</title>
            <description>Collection of specimens from symptomatic COVID-19 positive participants&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
          </group>
          <group group_id="O2">
            <title>Asymptomatic</title>
            <description>Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity</title>
          <description>Sensitivity (true positive rate) of antigen test in symptomatic participants compared with reference standard PCR test (at a threshold of &gt;=10^6 RNA copies/ml for positive PCR results)</description>
          <population>8 symptomatic participants with low RNA copy number were excluded for the calculation of the primary endpoint As this endpoint only considers the sensitivity in symptomatic participants, no numbers are shown for the asymptomatic group</population>
          <units>percentage of true cases</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="88.8" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Specificity</title>
        <description>Specificity (true negative rate) of antigen test in symptomatic participants compared with reference standard PCR test (at a threshold of &gt;=10^6 RNA copies/ml for positive PCR results)</description>
        <time_frame>Through study completion, an average of 1 1/2 month</time_frame>
        <population>8 symptomatic participants were excluded due to low RNA copy number As this endpoint only considers the specificity in symptomatic participants, no numbers are shown for the asymptomatic group</population>
        <group_list>
          <group group_id="O1">
            <title>Symptomatic</title>
            <description>Collection of specimens from symptomatic COVID-19 positive participants&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
          </group>
          <group group_id="O2">
            <title>Asymptomatic</title>
            <description>Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
          </group>
        </group_list>
        <measure>
          <title>Specificity</title>
          <description>Specificity (true negative rate) of antigen test in symptomatic participants compared with reference standard PCR test (at a threshold of &gt;=10^6 RNA copies/ml for positive PCR results)</description>
          <population>8 symptomatic participants were excluded due to low RNA copy number As this endpoint only considers the specificity in symptomatic participants, no numbers are shown for the asymptomatic group</population>
          <units>percentage of true negative cases</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="264"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="97.3" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity in Relation to the Cycle Threshold Value of the Reference RT-PCR (in the Symptomatic Group)</title>
        <description>Description of relationship between cycle threshold value of the reference RT-PCR and Dräger test performance.&#xD;
Presented is the sensitivity(true positive rate) in the symptomatic group at a cycle threshold of &lt;22</description>
        <time_frame>Through study completion, an average of 1 1/2 month</time_frame>
        <population>For the calculation of this endpoint only the PCR-positive participants from the symptomatic group were counted.</population>
        <group_list>
          <group group_id="O1">
            <title>Symptomatic</title>
            <description>Collection of specimens from symptomatic COVID-19 positive participants&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
          </group>
          <group group_id="O2">
            <title>Asymptomatic</title>
            <description>Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity in Relation to the Cycle Threshold Value of the Reference RT-PCR (in the Symptomatic Group)</title>
          <description>Description of relationship between cycle threshold value of the reference RT-PCR and Dräger test performance.&#xD;
Presented is the sensitivity(true positive rate) in the symptomatic group at a cycle threshold of &lt;22</description>
          <population>For the calculation of this endpoint only the PCR-positive participants from the symptomatic group were counted.</population>
          <units>percentage of true positive cases</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.8" lower_limit="88.7" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sensitivity in Relation to the Time Since Symptom Onset (in the Symptomatic Group)</title>
        <description>Description of relationship between days since symptom onset and Dräger test performance.&#xD;
Presented is the sensitivity(true positive rate) in the symptomatic group at days since symptom onset &lt;5</description>
        <time_frame>Through study completion, an average of 1 1/2 month</time_frame>
        <population>For the calculation of this endpoint only the PCR-positive participants from the symptomatic group were counted.</population>
        <group_list>
          <group group_id="O1">
            <title>Symptomatic</title>
            <description>Collection of specimens from symptomatic COVID-19 positive participants&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
          </group>
          <group group_id="O2">
            <title>Asymptomatic</title>
            <description>Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity in Relation to the Time Since Symptom Onset (in the Symptomatic Group)</title>
          <description>Description of relationship between days since symptom onset and Dräger test performance.&#xD;
Presented is the sensitivity(true positive rate) in the symptomatic group at days since symptom onset &lt;5</description>
          <population>For the calculation of this endpoint only the PCR-positive participants from the symptomatic group were counted.</population>
          <units>percentage of true positive cases</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="80.4" upper_limit="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specificity in Asymptomatic Participants</title>
        <description>Specificity of the antigen test in at least 100 asymptomatic participants</description>
        <time_frame>Through study completion, an average of 1 1/2 month</time_frame>
        <population>For the calculation of this endpoint only the PCR-negative participants from the asymptomatic group were counted.</population>
        <group_list>
          <group group_id="O1">
            <title>Symptomatic</title>
            <description>Collection of specimens from symptomatic COVID-19 positive participants&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
          </group>
          <group group_id="O2">
            <title>Asymptomatic</title>
            <description>Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
          </group>
        </group_list>
        <measure>
          <title>Specificity in Asymptomatic Participants</title>
          <description>Specificity of the antigen test in at least 100 asymptomatic participants</description>
          <population>For the calculation of this endpoint only the PCR-negative participants from the asymptomatic group were counted.</population>
          <units>percentage of true negative cases</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="100" lower_limit="96.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Nosebleed or Unbearable Pain During or Immediately After Specimen Collection</title>
        <description>Record of occurrence of lasting nosebleed or unbearable pain during or immediately after specimen collection</description>
        <time_frame>Through study completion, an average of 1 1/2 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symptomatic</title>
            <description>Collection of specimens from symptomatic COVID-19 positive participants&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
          </group>
          <group group_id="O2">
            <title>Asymptomatic</title>
            <description>Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Nosebleed or Unbearable Pain During or Immediately After Specimen Collection</title>
          <description>Record of occurrence of lasting nosebleed or unbearable pain during or immediately after specimen collection</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Symptomatic</title>
          <description>Collection of specimens from symptomatic COVID-19 positive participants&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
        </group>
        <group group_id="E2">
          <title>Asymptomatic</title>
          <description>Collection of specimens from asymptomatic participants who had known or suspected exposure to SARS-CoV-2&#xD;
Dräger Antigen Test SARS-CoV-2: Collection of patient samples using the Dräger sample collector with subsequent test reading via the Dräger Antigen SARS-CoV-2 Test</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Rainer Polzius</name_or_title>
      <organization>Draegerwerk AG &amp; Co. KGaA</organization>
      <phone>+498824514429</phone>
      <email>rainer.polzius@draeger.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

